Form 4: Phathom Pharmaceuticals CEO Terrie Curran Granted Stock Options

Phathom Pharmaceuticals' CEO, Terrie Curran, was granted stock options to purchase 342,500 shares of common stock on February 27, 2025, according to a Form 4 filing.

Summary

• This Form 4 filing reports a change in beneficial ownership for Terrie Curran, the President and CEO of Phathom Pharmaceuticals.
• On February 27, 2025, Ms. Curran was granted stock options to purchase 342,500 shares of Phathom Pharmaceuticals' common stock at an exercise price of $5.76 per share.
• The options vest over a four-year period, starting with 25% vesting on February 27, 2026, and the remainder vesting in equal monthly installments over the subsequent three years, contingent upon Ms. Curran's continued service to the company.
• Following this transaction, Ms. Curran directly owns 342,500 derivative securities in the form of stock options.

Sentiment

Score: 7

Explanation: The document itself is neutral, simply reporting a stock option grant. However, the grant is a positive sign of confidence in the CEO and the company's future, hence the slightly positive sentiment.

Positives

• The granting of stock options to the CEO aligns her interests with those of the shareholders, incentivizing her to improve the company's performance.
• The vesting schedule encourages long-term commitment from the CEO.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to attract and retain talent and align management's interests with those of shareholders. The size and vesting schedule of the grant are typical for a CEO of a company of Phathom Pharmaceuticals' size and stage.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options to incentivize their executives.
• The vesting schedule of these options, with a four-year vesting period, is consistent with industry norms.
• The number of shares granted and the exercise price would be benchmarked against peer companies of similar market capitalization and stage of development.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning management's interests with their own.
• Employees may see this as a sign of stability and commitment from the company to its leadership.

Key Dates